2025 Q3 -tulosraportti
Vain PDF
63 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
5 000
Myynti
Määrä
499
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 238 | - | - | ||
| 5 000 | - | - | ||
| 8 762 | - | - | ||
| 1 700 | - | - | ||
| 350 | - | - |
Ylin
4,7VWAP
Alin
4,3VaihtoMäärä
0,6 123 315
VWAP
Ylin
4,7Alin
4,3VaihtoMäärä
0,6 123 315
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 10.4.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenDon't understand the decline on that news. It has little or no impact on the company.
·9 t sittenProbably some nonsense, worst case 10 mill. but there will probably be a settlement of max 2 mill if anything comes of it at all. It seems like the entire old staff just wants to grab for themselves.
·33 min sittenTypical that Frode would have shares available in the account just before a potential deal😅- ·2 päivää sitten · MuokattuThe case has changed significantly in the last 24 hours. Based on the market engagement sent out from NHS, it appears that Induct is being positioned not only within severe asthma, but also COPD and early lung cancer. I previously thought this was a scenario 2–4 years away, but now it looks like NHS wants to elevate several respiratory pathways simultaneously. The moderate and severe COPD market is about 5 times larger than severe asthma. If Induct secures an agreement within both these verticals, and the rollout becomes national, we can approximately multiply the ARR estimate for severe asthma by 2,5. Lung cancer can provide an additional 40-50MNOK ARR. Then we have: Severe asthma: 75.000.000kr COPD: 187.000.000kr Lung cancer: 45.000.000kr Total: 307.000.000 With a 95% gross margin, slightly higher OPEX for increased operations, and a P/E of 12, the calculation will yield 88kr per share upon full rollout. This only applies to England, so further rollout to other countries will naturally lead to higher share prices. Such figures are merely illustrative until a concrete agreement is in place, but they say something about the potential. Remember that there is downside risk, and if they don't land a deal, it will be a disaster😊 Those who are shareholders and are not in the Dicorden should join.
·2 päivää sittenIt is possible that this has been a dynamic process that has evolved over time, but initially it was such that AZ would sponsor the license costs for a limited period, after which NHS (the public sector) would take over the bill. If AZ gets some discount, the most important thing will be what NHS pays in the long term. Agreed? Otherwise, it is important to point out that the UK is much more than just England, which will positively affect the calculations. - ·3 päivää sitten · MuokattuDug this up today: https://www.find-tender.service.gov.uk/Notice/002123-2026?origin=SearchResults&p=1 Positive, and quite concrete tendencies for Induct. Discussed on the Discord channel
- ·9.1.For those who wish, we have a very good forum on Discord with a dedicated page for Induct. A link will be provided in the comment section.·3 päivää sitten · Muokattuhttps://discord.com/channels/994563487810453544/1458437848121479168 This goes straight to the right channel
- ·8.1. · Muokattuhttps://www.healthcare-management.uk/nice-recommends-digital-platforms-help-patients-manage-asthma Things are happening in asthma now. These are apps approved for patient use. Induct works with software for clinicians, so Induct's software will serve as the backbone. The goal must surely be that these apps can connect to Induct's patient management system. This is the first time concrete recommendations within the digitalization of asthma are seen. Then I expect it's a very short time before Induct gets a deal.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
63 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenDon't understand the decline on that news. It has little or no impact on the company.·9 t sittenProbably some nonsense, worst case 10 mill. but there will probably be a settlement of max 2 mill if anything comes of it at all. It seems like the entire old staff just wants to grab for themselves.·33 min sittenTypical that Frode would have shares available in the account just before a potential deal😅
- ·2 päivää sitten · MuokattuThe case has changed significantly in the last 24 hours. Based on the market engagement sent out from NHS, it appears that Induct is being positioned not only within severe asthma, but also COPD and early lung cancer. I previously thought this was a scenario 2–4 years away, but now it looks like NHS wants to elevate several respiratory pathways simultaneously. The moderate and severe COPD market is about 5 times larger than severe asthma. If Induct secures an agreement within both these verticals, and the rollout becomes national, we can approximately multiply the ARR estimate for severe asthma by 2,5. Lung cancer can provide an additional 40-50MNOK ARR. Then we have: Severe asthma: 75.000.000kr COPD: 187.000.000kr Lung cancer: 45.000.000kr Total: 307.000.000 With a 95% gross margin, slightly higher OPEX for increased operations, and a P/E of 12, the calculation will yield 88kr per share upon full rollout. This only applies to England, so further rollout to other countries will naturally lead to higher share prices. Such figures are merely illustrative until a concrete agreement is in place, but they say something about the potential. Remember that there is downside risk, and if they don't land a deal, it will be a disaster😊 Those who are shareholders and are not in the Dicorden should join.·2 päivää sittenIt is possible that this has been a dynamic process that has evolved over time, but initially it was such that AZ would sponsor the license costs for a limited period, after which NHS (the public sector) would take over the bill. If AZ gets some discount, the most important thing will be what NHS pays in the long term. Agreed? Otherwise, it is important to point out that the UK is much more than just England, which will positively affect the calculations.
- ·3 päivää sitten · MuokattuDug this up today: https://www.find-tender.service.gov.uk/Notice/002123-2026?origin=SearchResults&p=1 Positive, and quite concrete tendencies for Induct. Discussed on the Discord channel
- ·9.1.For those who wish, we have a very good forum on Discord with a dedicated page for Induct. A link will be provided in the comment section.·3 päivää sitten · Muokattuhttps://discord.com/channels/994563487810453544/1458437848121479168 This goes straight to the right channel
- ·8.1. · Muokattuhttps://www.healthcare-management.uk/nice-recommends-digital-platforms-help-patients-manage-asthma Things are happening in asthma now. These are apps approved for patient use. Induct works with software for clinicians, so Induct's software will serve as the backbone. The goal must surely be that these apps can connect to Induct's patient management system. This is the first time concrete recommendations within the digitalization of asthma are seen. Then I expect it's a very short time before Induct gets a deal.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
5 000
Myynti
Määrä
499
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 238 | - | - | ||
| 5 000 | - | - | ||
| 8 762 | - | - | ||
| 1 700 | - | - | ||
| 350 | - | - |
Ylin
4,7VWAP
Alin
4,3VaihtoMäärä
0,6 123 315
VWAP
Ylin
4,7Alin
4,3VaihtoMäärä
0,6 123 315
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 10.4.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
63 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 10.4.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenDon't understand the decline on that news. It has little or no impact on the company.·9 t sittenProbably some nonsense, worst case 10 mill. but there will probably be a settlement of max 2 mill if anything comes of it at all. It seems like the entire old staff just wants to grab for themselves.·33 min sittenTypical that Frode would have shares available in the account just before a potential deal😅
- ·2 päivää sitten · MuokattuThe case has changed significantly in the last 24 hours. Based on the market engagement sent out from NHS, it appears that Induct is being positioned not only within severe asthma, but also COPD and early lung cancer. I previously thought this was a scenario 2–4 years away, but now it looks like NHS wants to elevate several respiratory pathways simultaneously. The moderate and severe COPD market is about 5 times larger than severe asthma. If Induct secures an agreement within both these verticals, and the rollout becomes national, we can approximately multiply the ARR estimate for severe asthma by 2,5. Lung cancer can provide an additional 40-50MNOK ARR. Then we have: Severe asthma: 75.000.000kr COPD: 187.000.000kr Lung cancer: 45.000.000kr Total: 307.000.000 With a 95% gross margin, slightly higher OPEX for increased operations, and a P/E of 12, the calculation will yield 88kr per share upon full rollout. This only applies to England, so further rollout to other countries will naturally lead to higher share prices. Such figures are merely illustrative until a concrete agreement is in place, but they say something about the potential. Remember that there is downside risk, and if they don't land a deal, it will be a disaster😊 Those who are shareholders and are not in the Dicorden should join.·2 päivää sittenIt is possible that this has been a dynamic process that has evolved over time, but initially it was such that AZ would sponsor the license costs for a limited period, after which NHS (the public sector) would take over the bill. If AZ gets some discount, the most important thing will be what NHS pays in the long term. Agreed? Otherwise, it is important to point out that the UK is much more than just England, which will positively affect the calculations.
- ·3 päivää sitten · MuokattuDug this up today: https://www.find-tender.service.gov.uk/Notice/002123-2026?origin=SearchResults&p=1 Positive, and quite concrete tendencies for Induct. Discussed on the Discord channel
- ·9.1.For those who wish, we have a very good forum on Discord with a dedicated page for Induct. A link will be provided in the comment section.·3 päivää sitten · Muokattuhttps://discord.com/channels/994563487810453544/1458437848121479168 This goes straight to the right channel
- ·8.1. · Muokattuhttps://www.healthcare-management.uk/nice-recommends-digital-platforms-help-patients-manage-asthma Things are happening in asthma now. These are apps approved for patient use. Induct works with software for clinicians, so Induct's software will serve as the backbone. The goal must surely be that these apps can connect to Induct's patient management system. This is the first time concrete recommendations within the digitalization of asthma are seen. Then I expect it's a very short time before Induct gets a deal.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
5 000
Myynti
Määrä
499
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 238 | - | - | ||
| 5 000 | - | - | ||
| 8 762 | - | - | ||
| 1 700 | - | - | ||
| 350 | - | - |
Ylin
4,7VWAP
Alin
4,3VaihtoMäärä
0,6 123 315
VWAP
Ylin
4,7Alin
4,3VaihtoMäärä
0,6 123 315
Välittäjätilasto
Dataa ei löytynyt